natgillin/translations-raw huggingface dataset:
Hos 10 børn med svær sepsis var Cmax 6, 1 mg/ l (område 4, 6- 8, 3 mg/ L) efter en 1- times intravenøs infusion i en dosis på 10 mg/ kg hos børn under 1 år sammenlignet med 7, 2 mg/ l (område 4, 7- 11, 8 mg/ l) hos børn mellem 1 og 5 år.
166 In 10 children with severe sepsis Cmax was 6.1 mg/ L (range 4.6-8.3 mg/ L) after a 1-hour intravenous infusion of 10 mg/ kg in children aged less than 1 year compared to 7.2 mg/ L (range 4.7-11.8 mg/ L) for children between 1 and 5 years of age.
Tryk skruelåget ned iht. vejledningen samtidig med, at det drejes til venstre.
167 Press down according to instructions on the cap while turning to the left.
Måleskeen skal bruges til afmåling af den foreskrevne mængde ciprofloxacinsuspension 50 mg/ ml..
The graduated measuring spoon with the markings 1/ 2 is equivalent to 2.6 mL containing 2.5 mL of final suspension and 1/ 1 is equivalent to 5.2 mL containing 5.0 mL of final suspension.
Ikke anvendte lægemidler samt affald heraf bør destrueres i henhold til lokale retningslinjer.
The graduated measuring spoon must be used for measuring the required prescribed amount of Ciprofloxacin oral suspension 100 mg/ mL.
171 {Navn og adresse} < {Tlf} > < {Fax} > < {Email} >
{Name and address }< {tel }> < {fax }> < {e-mail }>
172 1.
168 1.
Ciprofloxacin Bayer og tilhørende navne (se bilag I) 200 mg/ 100 ml infusionsvæske, opløsning [Se bilag I – Udfyldes nationalt]
Ciprofloxacin Bayer and associated names (see Annex I) 200 mg/ 100 mL solution for infusion [See Annex I - To be completed nationally]
Infusionsvæske, opløsning [Udfyldes nationalt]
[To be completed nationally]
Ciprofloxacin Bayer 200 mg/ 100 ml infusionsvæske, opløsning er indiceret til behandling af følgende infektioner (se pkt.
Ciprofloxacin Bayer 200 mg/ 100 mL solution for infusion is indicated for the treatment of the following infections (see sections 4.4 and 5.1).
4. 4 og 5. 1), Før behandling påbegyndes, skal tilgængelige oplysninger om resistens over for ciprofloxacin nøje studeres.
Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.
• Gastrointestinale infektioner (f. eks. rejsediaré)
• Infections of the gastro-intestinal tract (e. g. travellers ` diarrhoea)
173 • Infektioner i hud og bløddele forårsaget af gramnegative bakterier
• Infections of the skin and soft tissue caused by Gram-negative bacteria
• Infektioner i knogler og led
169 • Infections of the bones and joints
IV- behandling skal følges op med oral behandling så hurtigt som muligt.
IV treatment should be followed by oral route as soon as possible.
I svære tilfælde, eller hvis patienten ikke kan indtage tabletter (f. eks. patienter, som får enteral ernæring), bør behandlingen påbegyndes med intravenøs ciprofloxacin indtil det er muligt at skifte til oral indgift.
In severe cases or if the patient is unable to take tablets (e. g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.
174 Voksne
Adults
Daglig dosis
Daily dose in mg
Behandlingsvarighed (inklusiv skift til oral
Total duration of treatment (including switch to oral therapy as soon as possible)
behandling så hurtigt som muligt) Infektioner i de nedre luftveje
respiratory tract
400 mg to gange
400 mg twice daily to 400 mg three times a day
Infektioner i de øvre luftvej (iht. sværhedsgrad og
Infections of the upper respiratory tract
organisme)
Daily dose in mg
op til 3 måneder
Urinary tract
Kompliceret og
Complicated and
400 mg to gange
400 mg twice daily to
7- 21 dage, i nogle tilfælde kan
7 to 21 days, it can be
(iht. sværhedsgrad
infections
ukompliceret
uncomplicated pyelonephritis
tre gange dagligt
400 mg three times a day
end 21 dage (fx ved abscesser)
continued for longer than 21 days in some specific circumstances (such as abscesses)
2- 4 uger (akut)
2 to 4 weeks (acute)
dagligt op til 400 mg tre gange dagligt Genitale
Genital tract infections
Epididymoorchitis og
Epididymo-orchitis and pelvic inflammatory diseases
Gastrointestinale og intraabdorminale infektioner
Infections of the gastro-intestinal tract and intra- abdominal infections
Diaré forårsaget af bakterielle patogener, herunder Shigella spp. bortset fra Shigella dysenteriae type 1 og empirisk behandling af svær turistdiaré
Diarrhoea caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriae type 1 and empirical treatment of severe travellers’ diarrhoea
mg to gange dagligt
400 mg twice daily
5- 14 dage
5 days
dagligt op til 400 mg tre gange dagligt
Diarrhoea caused by Vibrio cholerae
7- 14 dage
3 days
dagligt op til 400 mg tre gange dagligt
Typhoid fever Intra-abdominal infections due to Gram-negative bacteria
175 Indikationer
400 mg twice daily 400 mg twice daily to 400 mg three times a day
Daglig dosis
7 days 5 to 14 days
Behandlingsvarighed (inklusiv skift til oral
Infections of the skin and soft tissue
behandling så hurtigt som muligt) Infektioner i knogler og led
400 mg twice daily to 400 mg three times a day
400 mg to gange
7 to 14 days
Højst i 3 måneder
Bone and joint infections
dagligt op til 400 mg tre gange dagligt Behandling af infektioner eller profylakse
400 mg twice daily to 400 mg three times a day
400 mg to gange
max. of 3 months
over for infektioner hos patienter med neutropeni Ciprofloxacin skal gives sammen med andre antibakterielle stoffer i henhold til officielle retningslinjer.
Treatment of infections or prophylaxis of infections in neutropenic patients Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance.
dagligt op til 400 mg tre gange dagligt
400 mg twice daily to 400 mg three times a day
hele neutropeniperioden
Therapy should be continued over the entire period of neutropenia
Behandlingen skal begynde så hurtigt som muligt efter mistanke om eller bekræftet eksponering.
Inhalation anthrax post-exposure prophylaxis and curative treatment for persons requiring parenteral treatment Drug administration should begin as soon as possible after suspected or confirmed exposure.
Indikationer
Indication
(inklusiv evt. parenteral behandling med ciprofloxacin) Cystisk fibrose
treatment (including switch to oral therapy as soon as possible) Cystic fibrosis
10 mg/ kg legemsvægt tre gange dagligt, maksimalt 400 mg pr. dosis.
10 mg/ kg body weight three times a day with a maximum of 400 mg per dose.
6 mg/ kg tre gange dagligt op til 10 mg/ kg legemsvægt tre gange dagligt, maksimalt 400 mg pr. dosis.
6 mg/ kg body weight three times a day to 10 mg/ kg body weight three times a day with a maximum of 400 mg per dose.
10 mg/ kg to gange dagligt op til 15 mg/ kg
10 mg/ kg body weight twice daily to 15 mg/ kg body
Behandlingen skal påbegyndes så hurtigt som muligt efter mistanke om eller bekræftet eksponerig.
post-exposure curative treatment for persons requiring parenteral treatment Drug administration should begin as soon as possible after suspected or confirmed exposure.
legemsvægt to gange dagligt, maksimalt 400 mg pr. dosis.
weight twice daily with a maximum of 400 mg per dose.
Ældre patienter skal have en dosis, der fastsættes ud fra infektionens alvorlighed og patientens kreatininclearance.
Geriatric patients should receive a dose selected according to the severity of the infection and the patient`s creatinine clearance.
176 Nedsat nyre - og leverfunktion
Renal and hepatic impairment
Intravenøs dosis [mg]
Intravenous Dose [mg]
normaldosering.
See Usual Dosage.
124- 168
124 to 168
200- 400 mg hver 12. time
200-400 mg every 12 h
200- 400 mg hver 24. time
200-400 mg every 24 h
200- 400 mg hver 24. time (efter dialyse)
200-400 mg every 24 h (after dialysis)
Ciprofloxacin skal anvendes til intravenøs infusion.
172 Ciprofloxacin should be administered by intravenous infusion.
Hos voksne patienter er infusionstiden 60 minutter for 400 mg ciprofloxacin og 30 minutter for 200 mg ciprofloxacin.
In adult patients, infusion time is 60 minutes for 400 mg Ciprofloxacin Bayer and 30 minutes for 200 mg Ciprofloxacin Bayer.
6. 2).
The infusion solution can be infused either directly or after mixing with other compatible infusion solutions (see section 6.2).
6. 1).
Hypersensitivity to the active substance, to other quinolones or to any of the excipients (see section 6.1).
4. 5).
Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).
177 Intra- abdominale infektioner Der er begrænsede data om virkningen af ciprofloxacin til behandling af postoperative intra - abdominale infektioner.
Intra-abdominal infections There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.
Behandlende læger skal henholde sig til national og/ eller international konsensusdokumentation om behandling af anthrax.
Treating physicians should refer to national and /or international consensus documents regarding the treatment of anthrax.
Ciprofloxacin- behandling må kun påbegyndes af en læge, der har erfaring i behandling af cystisk fibrose og/ eller svære infektioner hos børn og unge.
Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.
Sikkerhedsdata fra et randomiseret, dobbeltblindt studie om brug af ciprofloxacin til børn (ciprofloxacin: n=335, gennemsnitsalder = 6, 3 år; referencegruppe: n = 349, gennemsnitsalder = 6, 2 år, aldersområde:
Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin:
7, 2% og 4, 6%.
173 n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%.
9, 0% og 5, 7%.
Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%.
På grund af bivirkninger, som kan være relateret til led og/ eller det omgivende væv, bør behandlingen kun påbegyndes efter en omhyggelig vurdering af risici og fordele.
Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue.
178 Det muskuloskeletale system Ciprofloxacin bør generelt ikke bruges til patienter, som har haft senesygdomme relateret til behandling med quinoloner. ciprofloxacin kan dog i meget sjældne tilfælde ordineres til behandling af visse alvorlige infektioner efter mikrobiologisk dokumentation af den kausale organisme og en vurdering af risici og fordele.
Musculoskeletal System Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment.
Ved tegn på tendinitis (f. eks. smertefuld hævelse eller inflammation), skal behandlingen med ciprofloxacin seponeres.
At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued.
4. 8).
174 Ciprofloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain, burning, tingling, numbness, and/or weakness in order to prevent the development of an irreversible condition (see section 4.8).
179 Glucose- 6- phosphat dehydrogenase- mangel Hos patienter med glucose- 6- phosphat dehydrogenase- mangel er der indberetninger om hæmolytiske reaktioner ved behandling med ciprofloxacin.
Glucose-6-phosphate dehydrogenase deficiency Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency.
Der kan være en særlig risiko ved ciprofloxacin- resistente bakterier ved længere behandlingsforløb og ved behandling af nosokomielle infektioner og/ eller infektioner, der skyldes Staphylococcus - og Pseudomonas- arter.
There may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by Staphylococcus and Pseudomonas species.
Cytokrom P450 Ciprofloxacin hæmmer CYP1A2 og kan derfor medføre øgede serumkoncentrationer af lægemidler, som gives samtidigt, og som metaboliseres af dette enzym (f. eks. teofyllin, clozapin, ropinirol og tizanidin).
Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, ropinirole, tizanidine).
4. 5).
Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5).
Reaktioner på injektionstedet Der er indberetninger om lokale reaktioner på injektionsstedet efter intravenøs indgift af ciprofloxacin.
Injection Site Reaction Local intravenous site reactions have been reported with the intravenous administration of ciprofloxacin.
Glucosebelastning Ciprofloxacin infusionsopløsning indeholder 5 g glucose i 100 ml opløsning til infusion.
175 Glucose Load Ciprofloxacin Bayer solution for infusion contains 5 g glucose in 100 mL solution for infusion.
Virkninger af andre lægemidler på ciprofloxacin:
Effects of other medicinal products on ciprofloxacin:
180 Methotrexat
Methotrexate
Graviditet De oplysninger, der er tilgængelige vedrørende indgift af ciprofloxacin til gravide kvinder, tyder ikke på misdannelser eller foetotoksicitet hhv. neonatal toksicitet efter ciprofloxacin.
Pregnancy The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin.
181 Amning Ciprofloxacin udskilles i modermælk.
Lactation Ciprofloxacin is excreted in breast milk.
Bivirkningerne er sorteret efter hyppighed.
ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin Bayer (oral, intravenous and sequential therapy) sorted by categories of frequency are listed below.
Almindelig
Common ≥ 1/100 to <
Ikke almindelig
Uncommon ≥ 1/1 000 to <
Sjælden
Rare ≥ 1/10 000 to <
Meget
Very Rare < 1/ 10 000
Ukendt
Frequency not known
≥ 1/ 100 til <
1/100
≥ 1/ 1. 000 til
1/1 000
≥ 1/ 10. 000 til <
(cannot be estimated from available data)
sjælden
Infections and Infestations
hyppihed
Mycotic superinfections
1/ 10
177
< 1/ 100
Common ≥ 1/100 to <
1/ 1. 000
Uncommon ≥ 1/1 000 to <
< 1/ 10. 000
Very Rare < 1/ 10 000
(kan ikke
Frequency not known
beregnes fra de foreliggende data) Infektioner og parasitære sygdomme
1/ 10
Mykotiske superinfektioner
1/100
4. 4)
1/1 000
Petekkier Erythema multiforme Erythema nodosum Stevens - Johnson - syndrom (potentielt livstruende) Toksisk
Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening) Toxic epidermal necrolysis (potentially life- threatening)
183
179
Almindelig ≥ 1/ 100 til <
Common
Ikke almindelig ≥ 1/ 1. 000 til
Uncommon
Sjælden ≥ 1/ 10. 000 til
Rare
Meget < sjælden
Very Rare
Ukendt hyppihed
Frequency
1/ 10
Class
< 1/ 100
≥ 1/ 100 to <
1/ 1. 000
≥ 1/1 000 to <
< 1/ 10. 000
≥ 1/10 000 to <
(kan ikke
< 1/ 10 000
beregnes fra de foreliggende data) epidermal nekrolyse (potentielt livstruende) Knogler, led, muskler og bindevæv
not known
4. 4)
1/ 10
Nyrer og urinveje
1/100
Nedsat nyrefunktion
1/1 000
Nyresvigt Hæmaturi Krystalluri (se pkt.
(cannot be estimated from available data)
Reaktioner på injektions - og infusionsstedet (kun efter intravenøs indgift)
Injection and infusion site reactions (only intravenous administration)
Opkastning, forbigående transaminasestigninger, udslæt Trombocytopeni, trombocytæmi, konfusion og desorientering, hallucinationer, par - og dysæstesi, kramper, vertigo, synsforstyrrelser, tab af hørelse, takykardi, vasodilatation, hypotension, forbigående nedsat leverfunktion, gulsot, nyresvigt, ødemer
Vomiting, Transient increase in transaminases, Rash Thrombocytopenia, Thrombocytaemia, Confusion and disorientation, Hallucinations, Par- and dysaesthesia, Seizures, Vertigo, Visual disturbances, Hearing loss, Tachycardia, Vasodilatation, Hypotension, Transient hepatic impairment, Cholestatic icterus, Renal failure, Oedema
184 Børn Hyppigheden af ovennævnte artropati refererer til data, som stammer fra studier hos voksne.
The incidence of arthropathy, mentioned above, is referring to data collected in studies with adults.
Som et fluorquinolon- antibiotikum udøver Ciprofloxacin sin baktericide virkning ved at hæmme både type II topo- isomerase (DNA- gyrase) og top- isomerase IV, som er nødvendig for bakteriel DNA - replikation, transskription, genopretning og rekombination.
180 As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
PK/ PD- forholdet:
PK/PD relationship:
Impermeabilitet og/ eller resistens, som påvirker mekanismen af efflukspumpen for den aktive substans, kan have forskellig virkning på følsomheden over for fluoroquinoloner, hvilket afhænger af de fysiokemiske egenskaber hos forskellige aktive substanser inden for klassen og affiniteten af transportsystemerne for hver aktiv substans.
Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance.
185 Antibakterielt spektrum:
Spectrum of antibacterial activity:
S ≤ 0, 5 mg/ l S ≤ 0, 5 mg/ l S ≤ 1 mg/ l
S ≤ 0.5 mg/L S ≤ 0.5 mg/L S ≤ 1 mg/L S ≤ 1 mg/L
R > 1 mg/ l R > 1 mg/ l R > 1 mg/ l
R > 1 mg/L R > 1 mg/L R > 1 mg/L R > 1 mg/L
S ≤ 0, 03 mg/ l S ≤ 0, 03 mg / S ≤ 0, 5 mg/ l
S ≤ 0.03 mg/L S ≤ 0.03 mg/L S ≤ 0.5 mg/L
R > 0, 06 mg / R > 0, 06 mg / R > 1 mg/ l
> 0.06 mg/L > 0.06 mg/L R > 1 mg/L
Staphylococcus spp. - breakpoints for ciprofloxacin refererer til højdosisbehandling. * Ikke- artsrelaterede breakpoints er primært blevet bestemt på grundlag af PK/ PD- data, og er uafhængige af fordelingerne af MIC for specifikke arter.
1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy. * Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species.
ALMINDELIGE FØLSOMME ARTER Aerobe grampositive mikroorganismer Bacillus anthracis (1) Aerobe gramnegative mikroorganismer Aeromonas spp.
181 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis ($) Staphylococcus spp. *(2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia +* Campylobacter spp.+* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae * Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
187 Enteroccus faecium Listeria monocytogenes Aerobe gramnegative mikroorganismer Stenotrophomonas maltophilia Anaerobe mikroorganismer Undtagen ovennævnte Andre mikroorganismer Mycoplasma genitalium Ureaplasma urealitycum * Der er dokumenteret klinisk effekt for følsomme isolater ved godkendte indikationer + Resistensgrad ≥ 50% i et eller flere EU- lande ($):
182 INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications + Resistance rate ≥ 50% in one or more EU countries ($):
Den behandlende læge henvises til nationale og/ eller internationale konsensusdokumenter vedrørende behandling af anthrax.
The treating physician should refer to national and /or international consensus documents regarding treatment of anthrax.
En 60 minutters intravenøs infusion af 200 mg ciprofloxacin og en oral administration af 250 mg ciprofloxacin, begge givet hver 12. time, havde samme areal under serumkoncentrations/ tid- kurven (AUC).
A 60-minute intravenous infusion of 200 mg ciprofloxacin or the oral administration of 250 mg ciprofloxacin, both given every 12 hours, produced an equivalent area under the serum concentration time curve (AUC).
Ciprofloxacin findes overvejende uioniseret i plasma og har i steadystate et stort distributionsvolumen på 2- 3 l/ kg legemsvægt.
Ciprofloxacin
Ciprofloxacin når høje koncentrationer i mange væv som f. eks. lungevæv (epitelvæske, alveolære makrofager, biopsivæv), bihuler og inflammerede læsioner (cantharides blistervæske) og urogenitalsystemet (urin, prostata, endometrium), hvor totalkoncentrationerne kan overstige plasmakoncentrationerne.
183 reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.
188 Metabolisme
Metabolism
Udskillelse af ciprofloxacin (% af dosis) Intravenøs indgift
Excretion of ciprofloxacin (% of dose) Intravenous Administration
61, 5 9, 5
61.5 9.5
15, 2 2, 6
15.2 2.6
Den renale clearance er på 180 og 300 ml/ kg/ time og den totale bodyclearance er mellem 480 og 600 ml/ kg/ time.
Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h.
Der blev ikke set nogen bemærkelsesværdig stigning i Cmax og AUC efter gentagen dosering (10 mg/ kg tre gange dagligt).
No notable increase in Cmax and AUC upon multiple dosing (10 mg/kg three times daily) was observed.
Hos 10 børn med svær sepsis var Cmax 6, 1 mg/ l (område 4, 6- 8, 3 mg/ L) efter en 1- times intravenøs infusion i en dosis på 10 mg/ kg hos børn under 1 år sammenlignet med 7, 2 mg/ l (område 4, 7- 11, 8 mg/ l) hos børn mellem 1 og 5 år.
In 10 children with severe sepsis Cmax was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age.
17, 4 mg* h/ l (område 11, 8- 32, 0 mg* h/ l) og 16, 5 mg* h/ l (område 11, 0- 23, 8 mg* h/ l) i de respektive aldersgrupper.
The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.
Artikulær tolerance:
184 Articular tolerability:
189 hunde forårsagede ciprofloxacin alvorlige forandringer i leddene ved terapeutiske doser efter 2 ugers behandling, som stadig blev observeret efter 5 måneder.
In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.
Da infusionsopløsningen er lysfølsom, skal infusionsposerne tages ud af pakningen umiddelbart før brugen.
Since the infusion solution is photosensitive, the infusion bags should be removed from the box only immediately before use.